{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8927750_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"096-374-530-438-923","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11722,"type":"PATENT","title":"University of Cologne - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":488,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8375,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* koeln
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 343
Search Applicants and Owners separately:univ* Regensbu*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 324
Search Applicants and Owners separately: uni* koeln
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 343
Search Applicants and Owners separately:univ* Regensbu*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 324
X1, X2, X3, X4, Y1 and Y2 are, independently of each other, H, halogen, N3, cyano, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylsulfido, arylsulfido, alkylamino, arylamino, acyl, alkoxylcarbonyl, acylsulfanyl, acyloxy (—OC(═O)R1, acylamino (—N(R2)C(═O)R3 or phosphoryloxy (OP(═O)(R4)(R5),\nwherein,\n
R1 is H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino, alkylacyl, or arylacyl,\n
R2 and R3 are, independently of each other, H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino, alkylacyl, or arylacyl,\n
R4 and R5 are, independently of each other, OH, O− (as a salt), H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino,\n
each of the alkyl, the alkenyl, the alkylnyl, the aryl, the hetero-aryl, the alkoxy, the aryloxy, the alkylsulfido, the arylsulfido, the alkylamino, the arylamino, the acyl and the acylsulfanyl can be substituted by at least one of alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkoxy, aryloxy, acyl, hydroxy, amino, alkylamino, arylamino, halogeno, azido, oxo, imino, cyano and sulfanyl,\n
two or more of X1, X2, X3, X4, Y1 and Y2 may be connected to form a cyclic or polycyclic structure with an overall ring size of 5 to 20,\n
at least one of X1, X2, X3, X4, Y1 and Y2 must be at least one of acyloxy (—OC(═O)R1) and phosphoryloxy (OP(═O)(R4)(R5), wherein each of R1, R4 and R5 have the meaning as defined above, and\n
the following complexes are specifically excluded:\na) complexes having the formula (II):\nwherein R1, R2, R3, R4, R5, R6, R7 and R8 are, with respect to complexes 1-15, as set forth in Table 1:\nTABLE 1No.R1R2R3R4R5R6R7R81HHCH3CH3HHHCOMe2HHCH3CH3HHHP(O)(OEt)23HHCH3CH3HHHP(O)(Oi-Pr)24HHCH3CH3HHHP(O)(OPh)25HHCH3CH3HHHP(O)(NMe2)26HHHHCH3HHP(O)(OEt)27CH3HHHCH3HHP(O)(OEt)28CH3CH3HHCH3HHP(O)(OEt)29HHHHHHHP(O)(OEt)210HHHHHHHR*11HHHHHHHent-R*12HHHHOAcHHCOMe13CH3CH3HHOAcHHCOMe14HHCH3HHHHR*15HHCH3HHHHent-R*\nb) complexes having the formula (III):\nwherein R1 and R2 are, with respect to complexes 16-18, as set forth in Table 2:\nTABLE 2NoR1R216HR*17Hent-R*18CH3COMe\nc) complexes having the formula (IV):\nwherein R1, R2, R3, R4, R5 and R6 are, with respect to complexes 19-29, as set forth in Table 3:\nTABLE 3No.R1R2R3R4R5R619CH3HP(O)(OEt)2HC6H5H20CH3HP(O)(OEt)2HCH3H21HHP(O)(OEt)2HHH22HHP(O)(OEt)2Hi-PrH23HHP(O)(OEt)2HC6H5H24HHCOMeHHH25HHCOPhHHH26HHR*Hi-PrH27HHR*HC6H5H28HHent-R*Hi-PrH29HHent-R*HC6H5H\nd) complexes having the formula (V):\nwherein R1, R2, R3, R4, R5 and R6 are, with respect to complexes 30-36, as set forth in Table 4:\nTABLE 4No.R1R2R3R4R5R630HCO2MeHHCOMeH31HCOMeHHCOMEH32HCOPhHHCOMEH33HHHHCOMeH34HHHHCOPhH35CH3HHHR*H36CH3HHHent-R*H\ne) complexes having the formula (VI):\nwherein R1, R2, R3 and R4 are, with respect to complexes 37-46, as set forth in Table 5:\nTABLE 5No.R1R2R3R437HHHH38CH3HClH39CH3HCH3H40CH3HIH41HHClH42CH3HHH43CH3HBrH44HBrHH45HC6H5HH46HC6H5-4-OMeHH\nf) complexes having the formula (VII):\nwherein Ar and Rare, with respect to complexes 47-63, as set forth in Table 6:\nTABLE 6No.ArR47C6H5H48C6H5H49C6H5H50C6H4-2-MeH51C6H4-4-MeH52C6H4-3-ClH53C6H4-4-ClH54C6H5Me55C6H4-2-MeMe56C6H4-4-MeMe57C6H4-3-ClMe58C6H4-4-ClMe59C6H5Et60C6H4-2-MeEt61C6H4-4-MeEt62C6H4-3-ClEt63C6H4-4-ClEt\ng) complexes having the formula (VIII):\nwherein Ar and Rare, with respect to complexes 64-67, as set forth in Table 7:\nTABLE 7No.ArR64C6H5H65C6H5Me66C6H4-4-ClMe67C6H5Et\nh) complexes having the formula (X):\nwherein R1, R2, R3, R4 and R5 are, with respect to complexes 68-70, as set forth in Table 8:\nTABLE 8Nr.R1R2R3R4R568HC6H5C6H5C6H5C6H569C6H5 Ht-BuC6H5CO2Et70C6H5 Ht-BuC6H5SO2Me\nandi) complexes 71-73 below:\nwherein for complexes 1-73, Ac is acetyl, Bu is butyl, Me is methyl, Et is Ethyl, NME is N-methylamide, i-Pr is isopropyl, Pr is propyl, Ph is phenyl, R* is a substituent of the formula\nand ent-R* is an enantiomer of R*."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The complex as recited in claim 1, wherein in formula (I), Y1 and Y2 are connected to each other to form a carbocyclic or a heterocyclic ring with a ring size of 5 to 20."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The complex as recited in claim 1, wherein formula (I) includes stereoisomers and enantiomers arising from the complexation of non-symmetric diene ligands."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The complex as recited in claim 1, wherein the complex is at least one of complexes 80 to 99 and stereoisomers thereof:\n\n\nwherein Ph is phenyl, Ac is acetyl and TMS is trimethylsilyl."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A method of manufacturing the complex recited in claim 1, the method comprising at least one of methods a) to e):a) providing a dienylester ligand;\n
providing a Fe(CO)3 transfer reagent; and\n
complexing the dienylester ligand with the Fe(CO)3 transfer reagent to obtain the complex;\nb) providing an intermediate dienol-Fe(CO)3 complex; and\n
at least one of acylating and phosphorylating the intermediate dienol-Fe(CO)3 complex to obtain the complex;\nc) providing an intermediate acyloxy-diene complex; and\n
transesterifying the intermediate acyloxy-diene complex to obtain the complex;\nd) providing an acyl- or phosphoryloxy-substituted cationic pentadienyl-Fe(CO)3 complex; and\n
reacting the acyl- or phosphoryloxy-substituted cationic pentadienyl-Fe(CO)3with a nucleophile to obtain the complex; and\ne) providing an intermediate acyloxy- or phosphoryloxy-diene-Fe(CO)3 complex substituted with a reactive functional group; and\n
further reacting the intermediate acyloxy- or phosphoryloxy-diene-Fe(CO)3 complex substituted with a reactive functional group to obtain the complex."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method as recited in claim 5, wherein the dienylester ligand in a) is an acyloxy-diene or phosphoryloxydiene."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method as recited in claim 5, wherein the intermediate dienol-Fe(CO)3 complex in b) is a complex having the formula (I):\nwhere,\n
X1, X2, X3, X4, Y1 and Y2 are, independently of each other, H, halogen, N3, cyano, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylsulfido, arylsulfido, alkylamino, arylamino, acyl, alkoxylcarbonyl, acylsulfanyl, acyloxy (—OC(═O)R1, acylamino (—N(R2)C(═O)R3 or phosphoryloxy (OP(═O)(R4)(R5),\nwherein,\n
R1 is H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino, alkylacyl, or arylacyl,\n
R2 and R3 are, independently of each other, H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino, alkylacyl, or arylacyl,\n
R4 and R5 are, independently of each other, OH, O− (as a salt), H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino,\n
each of the alkyl, the alkenyl, the alkylnyl, the aryl, the hetero-aryl, the alkoxy, the aryloxy, the alkylsulfido, the arylsulfido, the alkylamino, the arylamino, the acyl and the acylsulfanyl can be substituted by at least one of alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkoxy, aryloxy, acyl, hydroxy, amino, alkylamino, arylamino, halogeno, azido, oxo, imino, cyano and sulfanyl,\n
two or more of X1, X2, X3, X4, Y1 and Y2 may be connected to form a cyclic or polycyclic structure with an overall ring size of 5 to 20, and\n
at least one of X1, X2, X3, X4 is OH,\nor the intermediate acyloxy-diene complex in c) is a complex having the formula (I):\nwhere,\n
X1, X2, X3, X4, Y1 and Y2 are, independently of each other, H, halogen, N3, cyano, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylsulfido, arylsulfido, alkylamino, arylamino, acyl, alkoxylcarbonyl, acylsulfanyl, acyloxy (—OC(═O)R1, acylamino (—N(R2)C(═O)R3 or phosphoryloxy (OP(═O)(R4)(R5),\nwherein,\n
R1 is H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino, alkylacyl, or arylacyl,\n
R2 and R3 are, independently of each other, H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino, alkylacyl, or arylacyl,\n
R4 and R5 are, independently of each other, OH, O− (as a salt), H, alkyl, alkenyl, alkynyl, aryl, hetero-aryl, alkoxy, aryloxy, alkylamino, arylamino,\n
each of the alkyl, the alkenyl, the alkylnyl, the aryl, the hetero-aryl, the alkoxy, the aryloxy, the alkylsulfido, the arylsulfido, the alkylamino, the arylamino, the acyl and the acylsulfanyl can be substituted by at least one of alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkoxy, aryloxy, acyl, hydroxy, amino, alkylamino, arylamino, halogeno, azido, oxo, imino, cyano and sulfanyl,\n
two or more of X1, X2, X3, X4, Y1 and Y2 may be connected to form a cyclic or polycyclic structure with an overall ring size of 5 to 20, and\n
at least one of X1, X2, X3, X4 contains at least one of acyloxy (—OC(═O)R1)."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method as recited in claim 5, wherein the reactive functional group in e) with which the intermediate acyloxy- or phosphoryloxy-diene-Fe(CO)3 complex is substituted is at least one of an alkynyl, a carboxyl, a ketone, an aldehyde, an amino, an azido and a hydroxy group."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A kit for producing a pharmaceutical solution, the kit comprising the complex as recited in claim 1 in solid form as an active ingredient and a pharmaceutically acceptable solvent."],"number":9,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}